Applicability of organ-on-chip systems in toxicology and pharmacology

References

• Ainslie GR, Davis M, Ewart L, Lieberman LA, Rowlands DJ, Thorley AJ, Yoder G, Ryan AM. 2019. Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective. Lab Chip. 19(19):3152–3161.
   PubMed Web of Science ®Google Scholar
• Alépée N, Bahinski A, Daneshian M, De Wever B, Fritsche E, Goldberg A, Hansmann J, Hartung T, Haycock J, Hogberg HT, et al. 2014. State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX. 31(4):441–477.
   PubMedGoogle Scholar
• Allwardt V, Ainscough AJ, Viswanathan P, Sherrod SD, McLean JA, Haddrick M, Pensabene V. 2020. Translational roadmap for the organs-on-a-chip industry toward broad adoption. Bioengineering. 7(3):112–127.
   Google Scholar
• Andrews PA, Blanset D, Costa PL, Green M, Green ML, Jacobs A, Kadaba R, Lebron JA, Mattson B, McNerney ME, et al. 2019. Analysis of exposure margins in developmental toxicity studies for detection of human teratogens. Regul Toxicol Pharm. 105:62–68.
   PubMed Web of Science ®Google Scholar
• Arık YB, van der Helm MW, Odijk M, Segerink LI, Passier R, van den Berg A, van der Meer AD. 2018. Barriers-on-chips: measurement of barrier function of tissues in organs-on-chips. Biomicrofluidics. 12(4):042218.
   PubMed Web of Science ®Google Scholar
• Auerbach S, Filer D, Reif D, Walker V, Holloway AC, Schlezinger J, Srinivasan S, Svoboda D, Judson R, Bucher JR, et al. 2016. Prioritizing environmental chemicals for obesity and diabetes outcomes research: a screening approach using ToxCast™ high-throughput data. Environ Health Perspect. 124(8):1141–1154.
   PubMed Web of Science ®Google Scholar
• Ball N, Cronin MTD, Shen J, Blackburn K, Booth ED, Bouhifd M, Donley E, Egnash L, Hastings C, Juberg DR, et al. 2016. Toward good read-across practice (GRAP) guidance. ALTEX. 33(2):149–166.
   PubMedGoogle Scholar
• Bal-Price A, Hogberg HT, Crofton KM, Daneshian M, FitzGerald RE, Fritsche E, Heinonen T, Hougaard Bennekou S, Klima S, Piersma AH, et al. 2018. Recommendation on test readiness criteria for new approach methods in toxicology: exemplified for developmental neurotoxicity. ALTEX. 35(3):306–352.
   PubMedGoogle Scholar
• Baudy AR, Otieno MA, Hewitt P, Gan J, Roth A, Keller D, Sura R, Van Vleet TR, Proctor WR. 2020. Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry. Lab Chip. 20(2):215–225.
   PubMed Web of Science ®Google Scholar
• Bell SM, Chang X, Wambaugh JF, Allen DG, Bartels M, Brouwer KLR, Casey WM, Choksi N, Ferguson SS, Fraczkiewicz G, et al. 2018. In vitro to in vivo extrapolation for high throughput prioritization and decision making. Toxicology in Vitro. 47:213–227.
   Google Scholar
• Beilmann M, Boonen H, Czich A, Dear G, Hewitt P, Mow T, Newham P, Oinonen T, Pognan F, Roth A, et al. 2019. Optimizing drug discovery by investigative toxicology: current and future trends. ALTEX. 36(2):289–313.
   PubMedGoogle Scholar
• Benam KH, Novak R, Nawroth J, Hirano-Kobayashi M, Ferrante TC, Choe Y, Prantil-Baun R, Weaver JC, Bahinski A, Parker KK, et al. 2016. Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst. 3(5):456–466.e454.
   PubMed Web of Science ®Google Scholar
• Ben-David U, Siranosian B, Ha G, Tang H, Oren Y, Hinohara K, Strathdee CA, Dempster J, Lyons NJ, Burns R, et al. 2018. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 560(7718):325–330.
   PubMed Web of Science ®Google Scholar
• Bos PMJ, Geraets L, De Wit-Bos L, Heringa M, Van Engelen J. 2020. Towards an animal-free human health assessment: starting from the current regulatory needs. ALTEX. 37(3):395–408.
   PubMedGoogle Scholar
• Burgdorf T, Piersma AH, Landsiedel R, Clewell R, Kleinstreuer N, Oelgeschläger M, Desprez B, Kienhuis A, Bos P, de Vries R, et al. 2019. Workshop on the validation and regulatory acceptance of innovative 3R approaches in regulatory toxicology – evolution versus revolution. Toxicol in Vitro. 59:1–11.
   PubMed Web of Science ®Google Scholar
• Campana O, Wlodkowic D. 2018. Ecotoxicology goes on a chip: embracing miniaturized bioanalysis in aquatic risk assessment. Environ Sci Technol. 52(3):932–946.
   PubMed Web of Science ®Google Scholar
• Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. 2009. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 27(3):275–280.
   PubMed Web of Science ®Google Scholar
• Choi KD, Yu J, Smuga-Otto K, Salvagiotto G, Rehrauer W, Vodyanik M, Thomson J, Slukvin I. 2009. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells. 27(3):559–567.
   PubMed Web of Science ®Google Scholar
• Conolly RB, Ankley GT, Cheng W, Mayo ML, Miller DH, Perkins EJ, Villeneuve DL, Watanabe KH. 2017. Quantitative adverse outcome pathways and their application to predictive toxicology. Environ Sci Technol. 51(8):4661–4672.
   PubMed Web of Science ®Google Scholar
• Cousins IT, Dewitt JC, Glüge J, Goldenman G, Herzke D, Lohmann R, Miller M, Ng CA, Scheringer M, Vierke L, et al. 2020. Strategies for grouping per- and polyfluoroalkyl substances (PFAS) to protect human and environmental health . Environ Sci Process Impacts. 22(7):1444–1460.
   PubMed Web of Science ®Google Scholar
• Czekanska EM, Stoddart MJ, Ralphs JR, Richards RG, Hayes JS. 2014. A phenotypic comparison of osteoblast cell lines versus human primary osteoblasts for biomaterials testing. J Biomed Mater Res A. 102(8):2636–2643.
   PubMed Web of Science ®Google Scholar
• Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J, Chen Z. 2017. Modeling physiological events in 2D vs. 3D cell culture. Physiology. 32(4):266–277.
   PubMed Web of Science ®Google Scholar
• ECHA. 2016. Practical guide: how to use alternatives to animal testing. Available from https://echa.europa.eu/documents/10162/13655/practical_guide_how_to_use_alternatives_en.pdf
   Google Scholar
• EMA. 2015. Reflection paper providing an overview of the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs. Available from https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-providing-overview-current-regulatory-testing-requirements-medicinal-products-human_en.pdf.
   Google Scholar
• Fabre K, Berridge B, Proctor WR, Ralston S, Will Y, Baran SW, Yoder G, Van Vleet TR. 2020. Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. Lab Chip. 20(6):1049–1057.
   PubMed Web of Science ®Google Scholar
• FDA. 2020. Qualification process for drug development tools. Guidance for industry and FDA staff. Available from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualification-process-drug-development-tools-guidance-industry-and-fda-staff.
   Google Scholar
• Ferreira GS, Veening-Griffioen DH, Boon WPC, Moors EHM, van Meer PJK. 2020. Levelling the translational gap for animal to human efficacy data. Animals. 10(7):1199–1113.
   Web of Science ®Google Scholar
• Fitzpatrick S, Sprando R. 2019. Advancing regulatory science through innovation: in vitro microphysiological systems. Cell Mol Gastroenterol Hepatol. 7(1):239–240.
   PubMed Web of Science ®Google Scholar
• Fragki S, Piersma AH, Rorije E, Zeilmaker MJ. 2017. In vitro to in vivo extrapolation of effective dosimetry in developmental toxicity testing: Application of a generic PBK modelling approach. Toxicology and Applied Pharmacology. 332:109–120.
   Google Scholar
• Gillet JP, Varma S, Gottesman MM. 2013. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 105(7):452–458.
   PubMedGoogle Scholar
• Hardwick RN, Betts CJ, Whritenour J, Sura R, Thamsen M, Kaufman EH, Fabre K. 2020. Drug-induced skin toxicity: gaps in preclinical testing cascade as opportunities for complex in vitro models and assays. Lab Chip. 20(2):199–214.
   PubMed Web of Science ®Google Scholar
• Hartung T, FitzGerald RE, Jennings P, Mirams GR, Peitsch MC, Rostami-Hodjegan A, Shah I, Wilks MF, Sturla SJ. 2017. Systems toxicology: real world applications and opportunities. Chem Res Toxicol. 30(4):870–882.
   PubMed Web of Science ®Google Scholar
• Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Hoffmann S, Roi AJ, et al. 2004. A modular approach to the ECVAM principles on test validity. Altern Lab Anim. 32(5):467–472.
   PubMed Web of Science ®Google Scholar
• Heringa MB, Park MVDZ, Kienhuis AS, Vandebriel RJ. 2020. The value of organs-on-chip for regulatory safety assessment. ALTEX. 37(2):208–222.
   PubMedGoogle Scholar
• Hoffmann S. 2015. LLNA variability: an essential ingredient for a comprehensive assessment of non-animal skin sensitization test methods and strategies. ALTEX. 32(4):379–383.
   PubMedGoogle Scholar
• Huang H, Song TJ, Li X, Hu L, He Q, Liu M, Lane MD, Tang QQ. 2009. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci U S A. 106(31):12670–12675.
   PubMed Web of Science ®Google Scholar
• Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Yuan Hsin H, Ingber DE. 2010. Reconstituting organ-level lung functions on a chip. Science. 328(5986):1662–1668.
   PubMed Web of Science ®Google Scholar
• ICH. 2011. ICH S6 (R1) guideline on preclinical safety evaluation of biotechnology-derived pharmaceuticals. Amsterdam: EMA.
   Google Scholar
• ICH. 2013. ICH M3 (R2) guideline on non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. Amsterdam: EMA.
   Google Scholar
• ICH. 2020. ICH S5 (R3) guideline on reproductive toxicology: detection of toxicity to reproduction for human pharmaceuticals – step 5. Amsterdam: EMA.
   Google Scholar
• Jackson EL, Lu H. 2016. Three-dimensional models for studying development and disease: moving on from organisms to organs-on-a-chip and organoids. Integr Biol. 8(6):672–683.
   Google Scholar
• Junying Y, Kejin H, Kim SO, Shulan T, Stewart R, Slukvin II, Thomson JA. 2009. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 324(5928):797–801.
   PubMed Web of Science ®Google Scholar
• Karmaus AL, Filer DL, Martin MT, Houck KA. 2016. Evaluation of food-relevant chemicals in the ToxCast high-throughput screening program. Food Chem Toxicol. 92:188–196.
   PubMed Web of Science ®Google Scholar
• Kieninger J, Weltin A, Flamm H, Urban GA. 2018. Microsensor systems for cell metabolism - from 2D culture to organ-on-chip. Lab Chip. 18(9):1274–1291.
   PubMed Web of Science ®Google Scholar
• Knapen D, Angrish MM, Fortin MC, Katsiadaki I, Leonard M, Margiotta-Casaluci L, Munn S, O'Brien JM, Pollesch N, Smith LC, et al. 2018. Adverse outcome pathway networks I: development and applications. Environ Toxicol Chem. 37(6):1723–1733.
   PubMed Web of Science ®Google Scholar
• Kolesky DB, Homan KA, Skylar-Scott M, Lewis JA. 2018. In vitro human tissues via multi-material 3-D bioprinting. Altern Lab Anim. 46(4):209–215.
   PubMed Web of Science ®Google Scholar
• Krebs A, Waldmann T, Wilks MF, van Vugt-Lussenburg BMA, van der Burg B, Terron A, Steger-Hartmann T, Ruegg J, Rovida C, Pedersen E, et al. 2019. Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data. ATLEX. 36(4):682–699.
   Google Scholar
• Kretzschmar K, Clevers H. 2016. Organoids: modeling development and the stem cell niche in a dish. Dev Cell. 38(6):590–600.
   PubMed Web of Science ®Google Scholar
• Lancaster MA, Knoblich JA. 2014. Organogenesisin a dish: modeling development and disease using organoid technologies. Science. 345(6194):1247125.
   PubMed Web of Science ®Google Scholar
• Li K, Yang X, Xue C, Zhao L, Zhang Y, Gao X. 2019. Biomimetic human lung-on-a-chip for modeling disease investigation. Biomicrofluidics. 13(3):031501.
   PubMed Web of Science ®Google Scholar
• Luechtefeld T, Maertens A, Russo DP, Rovida C, Zhu H, Hartung T. 2016. Analysis of draize eye irritation testing and its prediction by mining publicly available 2008-2014 REACH data. ALTEX. 33(2):123–134.
   PubMedGoogle Scholar
• Luechtefeld T, Marsh D, Rowlands C, Hartung T. 2018. Machine learning of toxicological big data enables read-across structure activity relationships (RASAR) outperforming animal test reproducibility. Toxicol Sci. 165(1):198–212.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GMM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2(6):875–894.
   PubMed Web of Science ®Google Scholar
• Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, Brendler-Schwaab S, Cirit M, David R, Dehne EM, et al. 2020. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX. 37(3):364–394.
   Google Scholar
• Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, et al. 2016. Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX. 33(3):272–321.
   PubMedGoogle Scholar
• Mastrangeli M, Millet S, Mummery C, Loskill P, Braeken D, Eberle W, Cipriano M, Fernandez L, Graef M, Gidrol X, et al. 2019. Building blocks for a European Organ-on-Chip roadmap. ALTEX. 36(3):481–492.
   PubMedGoogle Scholar
• Meneely PM, Dahlberg CL, Rose JK. 2019. Working with worms: Caenorhabditis elegans as a model organism. Curr Protoc Essent Lab Tech. 19(1):e35.
   Google Scholar
• Mirzoyan Z, Sollazzo M, Allocca M, Valenza AM, Grifoni D, Bellosta P. 2019. Drosophila melanogaster: a model organism to study cancer. Front Genet. 10:10.
   PubMed Web of Science ®Google Scholar
• Mittal R, Woo FW, Castro CS, Cohen MA, Karanxha J, Mittal J, Chhibber T, Jhaveri VM. 2019. Organ-on-chip models: implications in drug discovery and clinical applications. J Cell Physiol. 234(6):8352–8380.
   PubMed Web of Science ®Google Scholar
• Moné MJ, Pallocca G, Escher SE, Exner T, Herzler M, Bennekou SH, Kamp H, Kroese ED, Leist M, Steger-Hartmann T, et al. 2020. Setting the stage for next-generation risk assessment with non-animal approaches: the EU-ToxRisk project experience. Arch Toxicol. 94(10):3581–3592.
   PubMed Web of Science ®Google Scholar
• Nesmith AP, Agarwal A, McCain ML, Parker KK. 2014. Human airway musculature on a chip: an in vitro model of allergic asthmatic bronchoconstriction and bronchodilation. Lab Chip. 14(20):3925–3936.
   PubMed Web of Science ®Google Scholar
• Nikolova MP, Chavali MS. 2019. Recent advances in biomaterials for 3D scaffolds: a review. Bioact Mater. 4:271–292.
   PubMed Web of Science ®Google Scholar
• OECD. 2005. Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment. OECD Series on Testing and Assessment. No. 34. Paris: OECD.
   Google Scholar
• OECD. 2014. Guidance document for describing non-guideline in vitro test methods. OECD Series on Testing and Assessment. No. 211. Paris: OECD.
   Google Scholar
• OECD. 2016a. Guidance document for the use of adverse outcome pathways in developing integrated approaches to testing and assessment (IATA). OECD Series on Testing and Assessment. No. 260. Paris: OECD.
   Google Scholar
• OECD. 2016b. Guidance document on the reporting of defined approaches to be used within integrated approaches to testing and assessment. OECD Series on Testing and Assessment. No. 255. Paris: OECD.
   Google Scholar
• OECD. 2018. Guidance document on good in vitro method practices (GIVIMP). OECD Series on Testing and Assessment. No. 286. Paris: OECD.
   Google Scholar
• OECD. 2019. Guiding principles on good practices for the availability/distribution of protected elements in OECD test guidelines. OECD Series on Testing and Assessment. No. 298. Paris: OECD.
   Google Scholar
• Oleaga C, Riu A, Rothemund S, Lavado A, McAleer CW, Long CJ, Persaud K, Narasimhan NS, Tran M, Roles J, et al. 2018. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system. Biomaterials. 182:176–190.
   PubMed Web of Science ®Google Scholar
• Pagliuca FW, Millman JR, Gürtler M, Segel M, Van Dervort A, Ryu JH, Peterson QP, Greiner D, Melton DA. 2014. Generation of functional human pancreatic β cells in vitro. Cell. 159(2):428–439.
   PubMed Web of Science ®Google Scholar
• Paini A, Leonard JA, Joossens E, Bessems JGM, Desalegn A, Dorne JL, Gosling JP, Heringa MB, Klaric M, Kliment T, et al. 2019. Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making. Comput Toxicol. 9:61–72.
   PubMedGoogle Scholar
• Paini A, Leonard JA, Kliment T, Tan YM, Worth A. 2017. Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications. Regul Toxicol Pharmacol. 90:104–115.
   PubMed Web of Science ®Google Scholar
• Pamies D, Hartung T. 2017. 21st century cell culture for 21st century toxicology. Chem Res Toxicol. 30(1):43–52.
   PubMed Web of Science ®Google Scholar
• Pamies D, Bal-Price A, Chesné C, Coecke S, Dinnyes A, Eskes C, Grillari R, Gstraunthaler G, Hartung T, Jennings P, et al. 2018. Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems. ALTEX. 35(3):353–378.
   PubMedGoogle Scholar
• Park SE, Georgescu A, Huh D. 2019. Organoids-on-a-chip. Science. 364(6444):960–965.
   PubMed Web of Science ®Google Scholar
• Parrish J, Lim K, Zhang B, Radisic M, Woodfield TBF. 2019. New frontiers for biofabrication and bioreactor design in microphysiological system development. Trends Biotechnol. 37(12):1327–1343.
   PubMed Web of Science ®Google Scholar
• Patlewicz G, Lizarraga LE, Rua D, Allen DG, Daniel AB, Fitzpatrick SC, Garcia-Reyero N, Gordon J, Hakkinen P, Howard AS, et al. 2019. Exploring current read-across applications and needs among selected U.S. Federal Agencies. Regul Toxicol Pharmacol. 106:197–209.
   PubMed Web of Science ®Google Scholar
• Patterson EA, Whelan MP, Worth AP. 2021. The role of validation in establishing the scientific credibility of predictive toxicology approaches intended for regulatory application. Comput Toxicol. 17:100144.
   PubMedGoogle Scholar
• Perkins R, Fang H, Tong W, Welsh WJ. 2003. Quantitative structure-activity relationship methods: Perspectives on drug discovery and toxicology. Environ Toxicol Chem. 22(8):1666–1679.
   PubMed Web of Science ®Google Scholar
• Piersma AH, van Benthem J, Ezendam J, Kienhuis AS. 2018. Validation redefined. Toxicol in Vitro. 46:163–165.
   PubMed Web of Science ®Google Scholar
• Piersma AH, van Benthem J, Ezendam J, Staal YC, Kienhuis AS. 2019. The virtual human in chemical safety assessment. Curr Opin Toxicol. 15:26–32.
   Google Scholar
• Piersma AH, Burgdorf T, Louekari K, Desprez B, Taalman R, Landsiedel R, Barroso J, Rogiers V, Eskes C, Oelgeschläger M, et al. 2018. Workshop on acceleration of the validation and regulatory acceptance of alternative methods and implementation of testing strategies. Toxicol in Vitro. 50:62–74.
   PubMed Web of Science ®Google Scholar
• Piersma AH, Genschow E, Verhoef A, Spanjersberg MQI, Brown NA, Brady M, Burns A, Clemann N, Seiler A, Spielmann H. 2004. Validation of the postimplantation rat whole-embryo culture test in the international ECVAM validation study on three in vitro embryotoxicity tests. ATLA Alternatives to Laboratory Animals. 32(3):275–307.
   Google Scholar
• Pittman ME, Edwards SW, Ives C, Mortensen HM. 2018. AOP-DB: a database resource for the exploration of Adverse Outcome Pathways through integrated association networks. Toxicol Appl Pharmacol. 343:71–83.
   PubMed Web of Science ®Google Scholar
• Punt A, Bouwmeester H, Blaauboer BJ, Coecke S, Hakkert B, Hendriks DFG, Jennings P, Kramer NI, Neuhoff S, Masereeuw R, et al. 2020. New approach methodologies (NAMs) for human-relevant biokinetics predictions. Meeting the paradigm shift in toxicology towards an animal-free chemical risk assessment. ALTEX. 37(4):607–622.
   Google Scholar
• Roost MS, Slieker RC, Bialecka M, Van Iperen L, Gomes Fernandes MM, He N, Suchiman HED, Szuhai K, Carlotti F, De Koning EJP, et al. 2017. DNA methylation and transcriptional trajectories during human development and reprogramming of isogenic pluripotent stem cells. Nat Commun. 8(1):908.
   PubMedGoogle Scholar
• Rossi G, Manfrin A, Lutolf MP. 2018. Progress and potential in organoid research. Nat Rev Genet. 19(11):671–687.
   PubMed Web of Science ®Google Scholar
• Sackmann EK, Fulton AL, Beebe DJ. 2014. The present and future role of microfluidics in biomedical research. Nature. 507(7491):181–189.
   PubMed Web of Science ®Google Scholar
• Scialli AR, Daston G, Chen C, Coder PS, Euling SY, Foreman J, Hoberman AM, Hui J, Knudsen T, Makris SL, et al. 2018. Rethinking developmental toxicity testing: evolution or revolution? Birth Defects Res. 110(10):840–850.
   PubMedGoogle Scholar
• Shrestha J, Razavi Bazaz S, Aboulkheyr Es H, Yaghobian Azari D, Thierry B, Warkiani ME, Ghadiri M. 2020. Lung-on-a-chip: the future of respiratory disease models and pharmacological studies. Crit Rev Biotechnol. 40(2):213–230.
   PubMed Web of Science ®Google Scholar
• Smirnova L, Kleinstreuer N, Corvi R, Levchenko A, Fitzpatrick SC, Hartung T. 2018. 3S – systematic, systemic, and systems biology and toxicology. ALTEX. 35(2):139–162.
   PubMedGoogle Scholar
• Spinu N, Cronin MTD, Enoch SJ, Madden JC, Worth AP. 2020. Quantitative adverse outcome pathway (qAOP) models for toxicity prediction. Arch Toxicol. 94(5):1497–1510.
   PubMed Web of Science ®Google Scholar
• Tagle DA. 2019. The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development. Curr Opin Pharmacol. 48:146–154.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131(5):861–872.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Woltjen K, Miyake K, Hotta A, Ikeya M, Yamamoto T, Nishino T, Shoji E, Sehara-Fujisawa A, Manabe Y, et al. 2013. Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling miyoshi myopathy in vitro. PLoS One. 8(12):61540.
   Google Scholar
• Tavana H, Zamankhan P, Christensen PJ, Grotberg JB, Takayama S. 2011. Epithelium damage and protection during reopening of occluded airways in a physiologic microfluidic pulmonary airway model. Biomed Microdevices. 13(4):731–742.
   PubMed Web of Science ®Google Scholar
• Tetsuka K, Ohbuchi M, Kawabe T, Goto T, Kiyonaga F, Takama K, Yamazaki S, Fujimori A. 2020. Reconstituted human organ models as a translational tool for human organ response: Definition, expectations, cases, and strategies for implementation in drug discovery and development. Biol Pharm Bull. 43(3):375–383.
   PubMed Web of Science ®Google Scholar
• Tralau T, Oelgeschläger M, Gürtler R, Heinemeyer G, Herzler M, Höfer T, Itter H, Kuhl T, Lange N, Lorenz N, et al. 2015. Regulatory toxicology in the twenty-first century: challenges, perspectives and possible solutions. Arch Toxicol. 89(6):823–850.
   PubMed Web of Science ®Google Scholar
• van der Hee B, Madsen O, Vervoort J, Smidt H, Wells JM. 2020. Congruence of transcription programs in adult stem cell-derived jejunum organoids and original tissue during long-term culture. Front Cell Dev Biol. 8:375.
   PubMed Web of Science ®Google Scholar
• Van Meer PJK, Kooijman M, Van Der Laan JW, Moors EHM, Schellekens H. 2013. The value of non-human primates in the development of monoclonal antibodies. Nat Biotechnol. 31(10):882–883.
   PubMed Web of Science ®Google Scholar
• Van Meer PJK, Graham ML, Schuurman HJ. 2015. The safety, efficacy and regulatory triangle in drug development: impact for animal models and the use of animals. Eur J Pharmacol. 759:3–13.
   PubMed Web of Science ®Google Scholar
• Van Norman GA. 2019. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic Transl Sci. 4(7):845–854.
   PubMedGoogle Scholar
• Villeneuve DL, Angrish MM, Fortin MC, Katsiadaki I, Leonard M, Margiotta-Casaluci L, Munn S, O'Brien JM, Pollesch NL, Smith LC, et al. 2018. Adverse outcome pathway networks II: network analytics. Environ Toxicol Chem. 37(6):1734–1748.
   PubMed Web of Science ®Google Scholar
• Vinken M, Knapen D, Vergauwen L, Hengstler JG, Angrish M, Whelan M. 2017. Adverse outcome pathways: a concise introduction for toxicologists. Arch Toxicol. 91(11):3697–3707.
   PubMed Web of Science ®Google Scholar
• Wu Q, Liu J, Wang X, Feng L, Wu J, Zhu X, Wen W, Gong X. 2020. Organ-on-a-chip: recent breakthroughs and future prospects. Biomed Eng Online. 19(1):9.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. 2009. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 104(4):e30–e41.
   PubMed Web of Science ®Google Scholar
• Zhang YS, Aleman J, Shin SR, Kilic T, Kim D, Shaegh SAM, Massa S, Riahi R, Chae S, Hu N, et al. 2017. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci U S A. 114(12):E2293–E2302.
   PubMed Web of Science ®Google Scholar